Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:BTMD NASDAQ:CELU NASDAQ:CGTX NASDAQ:RLYB On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeBTMDbiote$2.13-5.1%$2.19$1.27▼$4.58$80.05M1.66252,217 shs617,951 shsCELUCelularity$0.70-8.4%$0.79$0.56▼$4.31$20.15M0.54140,184 shs236,100 shsCGTXCognition Therapeutics$0.92-0.6%$1.17$0.55▼$3.83$82.16M1.751.23 million shs255,148 shsRLYBRallybio$16.11-0.3%$15.88$3.20▼$17.57$85.40M-0.9171,636 shs12,162 shsThe 7 Hottest IPO Stories of 2026MarketBeat just released its list of the 7 hottest IPOs expected to hit Wall Street in 2026. See which companies are preparing to go public and why investors are watching closely.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceBTMDbiote-3.86%-11.11%+25.14%+0.90%-48.74%CELUCelularity+1.21%-6.16%+22.60%-20.82%-76.90%CGTXCognition Therapeutics-2.73%-7.65%-17.54%-21.74%+29.14%RLYBRallybio-0.92%-4.44%+1.00%+81.98%+301.03%Compare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeBTMDbiote$2.13-5.1%$2.19$1.27▼$4.58$80.05M1.66252,217 shs617,951 shsCELUCelularity$0.70-8.4%$0.79$0.56▼$4.31$20.15M0.54140,184 shs236,100 shsCGTXCognition Therapeutics$0.92-0.6%$1.17$0.55▼$3.83$82.16M1.751.23 million shs255,148 shsRLYBRallybio$16.11-0.3%$15.88$3.20▼$17.57$85.40M-0.9171,636 shs12,162 shsThe 7 Hottest IPO Stories of 2026MarketBeat just released its list of the 7 hottest IPOs expected to hit Wall Street in 2026. See which companies are preparing to go public and why investors are watching closely.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceBTMDbiote-3.86%-11.11%+25.14%+0.90%-48.74%CELUCelularity+1.21%-6.16%+22.60%-20.82%-76.90%CGTXCognition Therapeutics-2.73%-7.65%-17.54%-21.74%+29.14%RLYBRallybio-0.92%-4.44%+1.00%+81.98%+301.03%Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceBTMDbiote 2.50Moderate Buy$2.7529.41% UpsideCELUCelularity 2.00Hold$6.00762.07% UpsideCGTXCognition Therapeutics 2.50Moderate Buy$3.33263.11% UpsideRLYBRallybio 1.00SellN/AN/ACurrent Analyst Ratings BreakdownLatest CELU, RLYB, BTMD, and CGTX Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails7/6/2026CELUCelularity Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingUpgradeSell (E+) ➝ Sell (D-)6/24/2026CGTXCognition Therapeutics Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (D-)6/22/2026CGTXCognition Therapeutics HC WainwrightSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy$3.006/15/2026BTMDbiote Truist FinancialSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingUpgradeStrong-Buy5/28/2026BTMDbiote Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingUpgradeSell (D) ➝ Sell (D+)5/13/2026BTMDbiote Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingDowngradeSell (D+) ➝ Sell (D)5/8/2026RLYBRallybio Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (D-)(Data available from 7/29/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookBTMDbiote$192.22M0.42$0.53 per share4.01($1.40) per share-1.52CELUCelularity$26.55M0.76N/AN/A($1.32) per share-0.53CGTXCognition TherapeuticsN/AN/AN/AN/A$0.39 per shareN/ARLYBRallybio$860K99.29N/AN/A$10.98 per share1.47Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateBTMDbiote$27.05M$0.444.844.01N/A8.29%-25.72%15.12%8/5/2026 (Estimated)CELUCelularity-$91.72M-$3.33N/AN/AN/A-345.45%N/A-77.94%8/12/2026 (Estimated)CGTXCognition Therapeutics-$23.49M-$0.24N/AN/AN/AN/A-72.68%-53.07%8/6/2026 (Estimated)RLYBRallybio-$8.98M-$4.34N/AN/AN/A-911.07%-55.79%-51.48%8/6/2026 (Estimated)Latest CELU, RLYB, BTMD, and CGTX EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails8/6/2026Q2 2026CGTXCognition Therapeutics-$0.06N/AN/AN/A$5.00 millionN/A8/6/2026N/ARLYBRallybio-$1.28N/AN/AN/A$0.22 millionN/A8/5/2026Q2 2026BTMDbiote$0.07N/AN/AN/A$46.12 millionN/A5/13/2026Q1 2026RLYBRallybio-$1.20-$1.46-$0.26-$1.46$0.21 million$0.21 million5/7/2026Q1 2026CGTXCognition Therapeutics-$0.06-$0.05+$0.01-$0.05$4.40 millionN/A5/6/2026Q1 2026BTMDbiote$0.09$0.06-$0.03$0.06$46.02 million$44.94 million4/30/2026Q4 2025CELUCelularityN/A-$0.85N/A-$0.85N/A$4.10 millionCompare DividendsCompanyAnnual PayoutDividend Yield5-Year Annualized Dividend GrowthPayout RatioYears of Consecutive GrowthBTMDbioteN/AN/AN/AN/AN/ACELUCelularityN/AN/AN/AN/AN/ACGTXCognition TherapeuticsN/AN/AN/AN/AN/ARLYBRallybioN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioBTMDbioteN/A1.290.58CELUCelularityN/A0.150.15CGTXCognition TherapeuticsN/A5.925.92RLYBRallybioN/A12.9212.92Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipBTMDbiote21.68%CELUCelularity19.02%CGTXCognition Therapeutics43.35%RLYBRallybio90.34%Insider OwnershipCompanyInsider OwnershipBTMDbiote32.40%CELUCelularity17.30%CGTXCognition Therapeutics11.11%RLYBRallybio10.30%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableBTMDbiote19437.58 million25.41 millionNot OptionableCELUCelularity22028.95 million23.94 millionOptionableCGTXCognition Therapeutics2089.50 million79.56 millionNot OptionableRLYBRallybio405.30 million4.75 millionNot OptionableCELU, RLYB, BTMD, and CGTX HeadlinesRecent News About These CompaniesRallybio Corporation (NASDAQ:RLYB) Sees Significant Decline in Short InterestJuly 27 at 2:59 AM | marketbeat.comRallybio (NASDAQ:RLYB) Trading 1% Higher - Time to Buy?July 14, 2026 | marketbeat.comRallybio Investor Alert: Kahn Swick & Foti, LLC Investigates Merger of Rallybio Corporation - RLYBJune 2, 2026 | businesswire.comRallybio, Avenzo agree oncology reverse merger backed by $215 million financingJune 2, 2026 | thepharmaletter.comTRLYB Stock Hits 2-Year Highs After Unveiling Merger With Avenzo – How Much Of The New Company Will Rallybio Shareholders Own?June 1, 2026 | finance.yahoo.comRLYB Stock Alert: Halper Sadeh LLC is Investigating Whether Rallybio Corporation is Obtaining a Fair Price for its ShareholdersJune 1, 2026 | businesswire.comRallybio Corporation and Avenzo Therapeutics Announce Merger Agreement to Advance Next-Generation Oncology Therapies and $215 Million Concurrent Private PlacementJune 1, 2026 | businesswire.comRallybio CorporationMay 22, 2026 | edition.cnn.comRallybio (NASDAQ:RLYB) Major Shareholder Adar1 Capital Management, Llc Buys 6,009 SharesMay 21, 2026 | insidertrades.comAdar1 Capital Management buys $1.11m of Rallybio (RLYB) stockMay 16, 2026 | investing.comInsider Buying: Rallybio (NASDAQ:RLYB) Major Shareholder Purchases 79,259 Shares of StockMay 16, 2026 | insidertrades.comRallybio (NASDAQ:RLYB) Major Shareholder Adar1 Capital Management, Llc Acquires 800 SharesMay 14, 2026 | insidertrades.comRallybio (NASDAQ:RLYB) Major Shareholder Adar1 Capital Management, Llc Purchases 35,101 SharesMay 7, 2026 | insidertrades.comRallybio Receives Termination Fee After Candid Deal CollapseMay 4, 2026 | tipranks.comRallybio CMO Departs Amid Pending Candid Therapeutics MergerMarch 31, 2026 | tipranks.comCandid lists via Rallybio reverse merger, adds $505m financingMarch 5, 2026 | thepharmaletter.comTRallybio Investor Alert: Kahn Swick & Foti, LLC Investigates Merger of Rallybio Corporation - RLYBMarch 4, 2026 | businesswire.comRallybio Corp.March 3, 2026 | marketwatch.comRallybio Corporation and Candid Therapeutics Announce Merger AgreementMarch 2, 2026 | finance.yahoo.comRallybio Corporation (RLYB) M&A Call Prepared Remarks TranscriptMarch 2, 2026 | seekingalpha.comRallybio to Merge with Candid Therapeutics in All-Stock DealMarch 2, 2026 | tipranks.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeCELU, RLYB, BTMD, and CGTX Company Descriptionsbiote NASDAQ:BTMD$2.12 -0.12 (-5.13%) As of 03:09 PM Eastern This is a fair market value price provided by Massive. Learn more.biote Corp. operates in practice-building business within the hormone optimization space. It trains physicians and nurse practitioners in hormone optimization using bioidentical hormone replacement pellet therapy in men and women experiencing hormonal imbalance. The company offers Biote Method, a comprehensive end-to-end practice building platform that provides Biote-certified practitioners with the components developed for practitioners in the hormone optimization space comprising Biote Method education, training, and certification services; practice management software that allows Biote-certified practitioners to order, track, and manage hormone optimization product inventory and other administrative requirements; inventory management software to monitor pellet inventory; and information regarding available hormone replacement therapy products, as well as digital and point-of-care marketing support. It also sells dietary supplements under the Biote brand; and sterile pellet insertion kits that is used with hormone optimization therapies for male and female. The company was founded in 2012 and is headquartered in Irving, Texas.Celularity NASDAQ:CELU$0.70 -0.06 (-8.43%) As of 02:56 PM Eastern This is a fair market value price provided by Massive. Learn more.Celularity Inc., a clinical-stage biotechnology company, develops off-the-shelf placental-derived allogeneic cell therapies for the treatment of cancer, immune, and infectious diseases. It operates through three segments: Cell Therapy, Degenerative Disease, and BioBanking. The company's lead therapeutic programs include CYCART-19, an allogeneic CAR-T cell for the treatment of non-Hodkin's lymphoma (NHL) and mantle cell lymphoma (MCL); CYNK-001, an allogeneic unmodified natural killer cell that is in Phase I/II clinical trial for the treatment of acute myeloid leukemia (AML); and APPL-001, a genetically modified placental-derived mesenchymal-like adherent stromal cell for the treatment of Crohn's disease. It is also developing CYCART-201 for the treatment of NHL and MCL, and human epidermal growth factor receptor 2 positive cancers; CYNK-301, a next generation chimeric antigen receptor-natural killer (CAR-NK) for treating relapse refractory AML; CYNK-302, a CAR-NK to treat non-small cell lung cancer; and pExo-001, a human postpartum placenta derived exosome product for the treatment of osteoarthritis. It also produces, sells, and licenses products that are used in surgical and wound care markets, such as Biovance, Biovance 3L, Interfyl, and Centaflex; and collects and stores stem cells from umbilical cords and placentas under the LifebankUSA brand. The company has licensing agreement with Sorrento Therapeutics, Inc. for the development and commercialization of licensed CD19 CAR-T products; and research collaboration services agreement with Regeneron Pharmaceuticals, Inc. to support the research of allogeneic cell therapy candidates. The company was founded in 1998 and is based in Florham Park, New Jersey.Cognition Therapeutics NASDAQ:CGTX$0.92 -0.01 (-0.60%) As of 03:11 PM Eastern This is a fair market value price provided by Massive. Learn more.Cognition Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in the discovery and development of small molecule therapeutics targeting age-related degenerative diseases and disorders of the central nervous system and retina. Its lead product candidate is CT1812, an orally delivered molecule modulator designed to penetrate the blood-brain barrier and bind selectively to the S2R complex, which is in Phase 2 clinical trial for the treatment of Alzheimer's disease, as well as geographic atrophy secondary to dry age-related macular degeneration and synucleinopathies, such as dementia with Lewy bodies. The company was incorporated in 2007 and is headquartered in Purchase, New York.Rallybio NASDAQ:RLYB$16.11 -0.05 (-0.30%) As of 03:11 PM Eastern This is a fair market value price provided by Massive. Learn more.Rallybio Corporation, a clinical-stage biotechnology company, engages in development and commercialization of life-transforming therapies for patients suffering from severe and rare diseases. Its lead product candidate is RLYB212, a monoclonal anti-HPA-1a antibody that has completed Phase I clinical trial for the prevention of fetal and neonatal alloimmune thrombocytopenia (FNAIT); and RLYB211 for the prevention of FNAIT. The company is also developing RLYB114, a pegylated complement factor 5 (C5)-targeted Affibody molecule in preclinical development for the treatment of complement-mediated ophthalmic diseases; RLYB116, an inhibitor of complement component 5 (C5) to treat several diseases of complement dysregulation which has completed phase 1 trial; and RLYB331, a preclinical antibody, for the treatment of severe anemia with ineffective erythropoiesis and iron overload. It entered into a strategic alliance with AbCellera to discover, develop, and commercialize novel antibody-based therapeutics for rare diseases. Rallybio has collaboration with Exscientia for the development of small molecule therapeutics for rare diseases; and collaboration agreement with Johnson & Johnson to provide pregnant individuals therapeutic solutions at risk of fetal and neonatal alloimmune thrombocytopenia. The company was founded in 2018 and is headquartered in New Haven, Connecticut. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSilverSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas Why SK hynix Could Be the Best AI Chip Stock to Buy Now Why Bloom Energy May Be the Most Important AI Infrastructure Stock Alphabet Is Down 18% From Its High After a Stellar Quarter—Overdone, or More Downside Ahead? Seagate Technology Stock Surges as Earnings Beat Silences AI Doubters Broadcom’s $200 Billion Samsung Deal Shows How Costly the AI Memory Race Has Become Meta’s AI Spending Problem Just Found a BlackRock Solution Carrier Earnings Could Send the Stock to a New All-Time High Amazon’s Satellite Push Raises the Stakes for SpaceX and AST SpaceMobile Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
